Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Ipsen (Paris:IPN) announced today the initiation of dosing in two phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.

“After the encouraging signs of efficacy observed in the first clinical studies in healthy as well as acromegalic volunteers, we look forward to further investigating BIM 23A760 efficacy and safety in patients with neuroendocrine tumors or acromegaly. This very promising compound is core to Ipsen’s strategy to enhance its fast-growing and competitive endocrinology franchise, featuring among other drugs Somatuline^®, a somatostatin analogue developed and marketed on a global scale” said Stéphane Thiroloix, Executive Vice-President, Corporate Development, Ipsen.

Source Ipsen